The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
TCL
Vol.
37
No.
08
February 25, 2011
CCL
Vol.
34
No.
2
February 25, 2011
- Avastin Phase III Trial Meets Endpoint: PFS in Platinum-Sensitive Ovarian Cancer
- Iniparib Doesn’t Meet Survival, PFS Endpoints In Phase III Trial in Triple-Negative Breast Cancer
- Sentinel Node Disection No Worse Than Axillary
- Triple-Negative Breast Cancer Equally Aggressive in Whites
- RG7204 Meets Endpoints Of Extending Survival, PFS
- INSPIRE Enrollment Stopped; Thromboembolism Risk Cited
- Tarceva Reaches Endpoint Early: Longer PFS Than Chemo Alone
- mTOR Inhibitor Improves PFS In Metastatic Sarcoma Patients
- Afinitor Tablet Doubles PFS; Lowers Progression Risk 65%
- Study Links Native American Ancestry to Leukemia Relapse
- Study Explores Reasons Women Avoid Mammograms
- Hormone Therapy At Menopause Linked to More Breast Cancer Risk
- Children of Male Cancer Survivors Have Highrt Risk of Birth Defects
- Study Finds No Link Between Tumor Grade and Relapse Risk
- Clinical Trials Approved By NCI CTEP Last Month
- Rituxan Approved as Maintenance For Advanced Follicular Lymphoma
TCL
Vol.
37
No.
12
March 25, 2011
- Why Four? NCI Official Challenged To Explain Rational For Proposed Number Of Groups
- An Alliance of NSABP-RTOG And GOG?
- Pazdur: Registration Trials Run By Groups Need Same Rigor As Industry Trials
- McCormick President-Elect of AACR; Garber To Start Term As President
- BMS Agent Yervoy Received FDA Approval for Metastatic Melanoma
CCL
Vol.
34
No.
3
March 25, 2011
- Rituximab and Fludarabine Combination Produces Long-Term Remissions in CLL
- Two-Year Remission While Taking Gleevec Puts Patients Into Normal Mortality Rate
- XGEVA not Inferior to Zometa In 1,776-Patient Phase III Study
- Study Suggests Biomarker For Resistance to Tamoxifen
- Radiation, Tamoxifen After Surgery Reduce Breast Cancer Occurrence
- Aflibercept-Docetaxel Combination Misses Primary Survival Endpoint
- Patients Who Smoke In Treatment Do Worse Than Those Who Quit
- Dendritic Cell Vaccine May Boost Median Survival
- Decline In Breast Cancer May Be Related to Drop In HT
- Triple-Negative Breast Cancer Increases With Number of Births
- PSA Velocity Poor Predictor Of Prostate Cancer Occurrence
- Statins Associated With Lower Risk Of High-Grade Prostate Cancer
- Mentholated Cigarettes Cause No More Lung Cancer, Deaths
- Clinical Trials Approved By NCI CTEP Last Month
- FDA Approves BMS’s Yervoy For Metastatic Melanoma